Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Clinical and Research Excellence Index

Close Icon

Events

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

pharmaceutical companies pharma intelligence

The partner of choice for pharmaceutical companies

Bring game-changing drugs to market more efficiently. We’ll help you understand the competition to hone in on your strategies to improve healthcare and patient outcomes.

Get drugs to market faster

adevelopment partner pharma intelligence

The right drugs developed at the right time transform pharmaceutical and biotechnology companies and improve patients’ lives. But the process is long and complex, taking place in an ever-changing, intensely competitive arena.

How we help
As the trusted pharma research partner of the top 50 global pharmaceutical companies, we provide reliable, timely intelligence and insights to help you every step of the way during drug development.

We can help you:

Optimize your clinical trials
Stay ahead of the competition by fully understanding future patient needs
Tailor your portfolio and commercial strategies to market needs
Identify opportunities and overcome potential threats across your pipeline
Stay current and be prepared for market shifts
Access historical success rates, and development and regulatory durations from a large number of perspectives

Our unique strengths

Identify market opportunities

Understand where future drug and development opportunities lie with access to the industry’s leading forecasts and behind-the-headlines analysis.

Capitalize on treatment trends

Keep on top of global trends and access source information on the impact of developing technologies.

Approach reimbursement proactively

Our reimbursement analysis can assist your business planning – both at the early stages of product development and long after product launch.

View competitor activity

Get unique competitor insight with our detailed reviews of your competitors’ clinical trials and our ability to track all drugs in development.

View more
View Less

Relevant products

Trialtrove: gold standard clinical trials intelligence

Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.

Key benefits:

Curated by experts
Clinical trial landscape view
Ask-the-Analyst™

Biomedtracker: see the drug development process through analysts’ eyes

Real-time tracking and analysis of the drug development pipeline

Key benefits:

Market Events & Catalysts
Likelihood of Approval
Deals Coverage

Scrip: industry news and insights

Key benefits:

Follow market developments
Go beyond the news
Hear from news makers

View all content

Scrip

Kancera Targets COVID-19 With Fractalkine Inhibitor

Sweden-based Kancera hopes to advance its investigative anti-inflammation drug in a Phase II trial to treat severe COVID-19 patients and then build its applications from there.

Topic Coronavirus Clinical Trials

View article
Scrip

Finance Watch: Atea Pharmaceuticals Raises $215m For COVID-19 Antiviral

Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.

Topic Coronavirus Financing Innovation

View article
Scrip

China Still Leading Vaccines Race Despite Moderna Data, US 'Warp Speed' Plan?

The unveiling of US president Donald Trump’s 'Warp Speed’ plan to fast-track a coronavirus vaccine and the latest promising Phase I data from Moderna's candidate haven't seemed to swing China’s belief that it’s still leading the race.

Topic Coronavirus

View article
Scrip

Moderna’s Early Data Gives Big Boost For COVID-19 Vaccine Hopes

First eight volunteers produced antibodies which match or surpass those seen in patients who have recovered from COVID-19 – but big test awaits in Phase III.

Topic Coronavirus

View article
Awareness, Lead generation, Our products and audiences

Powering Pharma and Medtech To Make Effective Clinical Regulatory and Commercial Decisions

With deep Pharma industry and marketing expertise, we can help you to reach Pharma’s elusive decision makers with relevant high-impact and engaging content, so you can reach your business and revenue objectives.

Topic Market Intelligence

View infographic
Awareness, Lead generation

Top 5 Tips for Producing Successful Webinars

Get valuable tips to maximize your webinar success from Informa Pharma Intelligence when you download our infographic. Learn the proven tactics our pharma marketing experts employ when planning our own webinar events

Topic Advertising, Marketing & Sales

View infographic
Lead generation, Thought leadership

5 Top Tips For Generating Successful Content Marketing

From choosing the right audience to measuring campaign results, follow these 5 tips when planning your successful content marketing campaign.

Topic Advertising, Marketing & Sales

View infographic
HBW Insight

CBD News Round-Up: Australia Proposes OTC Pathway, First EU Novel Food Validation, COVID Boost For UK Firm

Australia looks at switching CBD as an OTC medicine, CBDepot becomes the first European firm with an EU Novel Food validation and the UK's Vitality CBD gets a boost from the global, coronavirus-driven wellness trend.

Topic Dietary Supplements Coronavirus

View article
HBW Insight

IFRA Chair Looks Forward To Post-COVID-19 ‘Revival Of Reason’

IFRA’s new chairman Hans Holger Gliewe says one possible positive outcome of the COVID-19 pandemic could be that consumers go on putting a premium on scientific expertise after months of reliance on health experts’ advice.

Topic Coronavirus Cosmetics

View article
Scrip

Pharma Can Reset Reputation In Pandemic, Says Novartis CEO

Vas Narasimhan hopes that donations and the "unprecedented collaborations" between drugmakers trying to overcome the COVID-19 pandemic is leading to a shift in the perception of the value of the sector to society.

Topic Coronavirus Leadership Strategy

View article
Scrip

Gilead’s Major Challenge Is Sustainable Model For Remdesivir

With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.

Topic Coronavirus Sales Earnings Business Strategies

View article
Scrip

Sanofi/Regeneron Refocus Kevzara COVID-19 Trial On Critical Patients, Showing Value Of A Proper Trial

A Phase III trial testing Kevzara in hospitalized COVID-19 patients will continue only with the high dose in more advanced critical patients after the low-dose was unsuccessful.

Topic Coronavirus Clinical Trials Research & Development

View article
Scrip

Bayer Adds Up COVID-19 Pluses and Minuses In Q1

Bayer has beaten analyst forecasts for the first quarter but says the uncertainties brought about by the coronavirus pandemic prevent it from issuing financial guidance for the full year.

Topic Coronavirus Sales Earnings

View article
Generics Bulletin

Celltrion Sets Out Plans To Trial Coronavirus Treatments

In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.

Topic Coronavirus

View article
HBW Insight

Bayers Supplement Sales Leap By A Third On COVID Boost

Bayer posts double-digit rise in Q1 Consumer Health sales off the back of unprecedented demand for its dietary supplements in the middle of the global coronavrius pandemic.

Topic Coronavirus

View article